Tucker Asset Management LLC Sells 190 Shares of Novo Nordisk A/S (NYSE:NVO)

Tucker Asset Management LLC lessened its position in Novo Nordisk A/S (NYSE:NVO) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,867 shares of the company’s stock after selling 190 shares during the quarter. Tucker Asset Management LLC’s holdings in Novo Nordisk A/S were worth $297,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. CNB Bank bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $26,000. Pacific Center for Financial Services raised its stake in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Valued Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Frank Rimerman Advisors LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $30,000. Finally, Tyler Stone Wealth Management increased its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after buying an additional 146 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $0.01 during trading on Friday, reaching $142.50. 2,831,653 shares of the stock were exchanged, compared to its average volume of 3,320,250. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $144.50. The stock has a 50-day moving average price of $131.39 and a 200-day moving average price of $120.48. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The firm has a market cap of $639.47 billion, a PE ratio of 49.14, a PEG ratio of 1.47 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Research analysts expect that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets started coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Finally, Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.